D
Derek Carr
Researcher at FHI 360
Publications - 18
Citations - 583
Derek Carr is an academic researcher from FHI 360. The author has contributed to research in topics: Opioid overdose & Naloxone. The author has an hindex of 9, co-authored 17 publications receiving 445 citations. Previous affiliations of Derek Carr include University of North Carolina at Chapel Hill & Brown University.
Papers
More filters
Journal ArticleDOI
Legal changes to increase access to naloxone for opioid overdose reversal in the United States.
Corey S. Davis,Derek Carr +1 more
TL;DR: While these laws will likely reduce overdose morbidity and mortality, the cost of naloxone and its prescription status remain barriers to more widespread access.
Journal ArticleDOI
State legal innovations to encourage naloxone dispensing
Corey S. Davis,Derek Carr +1 more
TL;DR: Pharmacists are key members of the health care team and are uniquely situated to reduce potential opioid overdose risk and should be aware of and utilize innovative state laws designed to increase access to naloxone.
Journal ArticleDOI
Physician continuing education to reduce opioid misuse, abuse, and overdose: many opportunities, few requirements
Corey S. Davis,Derek Carr +1 more
TL;DR: While not a replacement for improved education in medical school and post-graduate clinical training, evidence-based CME can help improve provider knowledge and practice and may help reduce opioid-related morbidity and mortality.
Journal ArticleDOI
Engaging Law Enforcement in Overdose Reversal Initiatives: Authorization and Liability for Naloxone Administration
TL;DR: This work systematically examined the legal risk associated with LEO naloxone administration and found that liability risks related to naloxin administration are similar to or lower than those of other activities in which LEOs commonly engage.
Journal ArticleDOI
Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States
Corey S. Davis,Derek Carr +1 more
TL;DR: It is argued that jurisdictions should proactively offer opioid agonist therapy to individuals at high risk of overdose, remove barriers to establishing methadone treatment facilities, and address underlying social determinants and barriers to treatment.